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a  b  s  t  r  a  c  t
Introduction:  Diverticular  disease  (DD), a herniation  of  the  colonic  mucosa  through  the muscle  layer,  cov-
ers a wide  variety  of conditions  associated  with  the  presence  of  diverticula  in  the  colon.  The  most  serious
form  is  an  acute  episode  of diverticulitis,  which  can lead  to hospitalization  and surgery  with  various  types
of consequences.  The  main  aim  of this  study  is  to evaluate  the  economic  burden  of hospitalizations  arising
from  acute  episodes  of  diverticulitis  using  data  from  the  administrative  databases  used  in  the  Marche
region  in  Italy  and, as  a secondary  objective  of this  real-world  data  analysis,  to  study  patient  outcome
variables  following  initial  hospitalization  for  diverticulitis.
Method:  A  deterministic  linkage  was  performed  at individual  user  level  between  the  different  adminis-
trative  sources  of  the  Marche  region  through  anonymous  ID number  for a  period  of  analysis  between
1  January,  2008  and  31  December,  2014.  We  enrolled  all  patients  with  at least  one  hospitalization  for
“diverticulitis  of the  colon  without  mention  of  haemorrhage”  (ICD-9-CM  code  562.11) or “diverticulitis  of
the colon  with  haemorrhage”  (ICD-9-CM  code  562.13)  as  primary  or secondary  diagnosis.  For  each  patient
we assessed  the cost  of  hospitalization,  of  medicines  and  of  specialist  services  considering  a  time-scale
of  one  year  or  cohort  analysis  365  days  after  ﬁrst  admission.
Results:  The  total  number  of residents  in the  Marche  region  who  had  at least  one hospitalization  for
diverticulitis  in  the  period  2008–2014  was  2987  (427  patients  a year,  corresponding  to  about  35 patients
per  100,000  adult  residents);  the  total  number  of  admissions  was  3453  (just  over 490  a year).  The  direct
healthcare  costs  incurred  by the  Marche  region  for episodes  of  diverticulitis  in 2008–2014  amounted
to  approximately  D 11.4  million  (D 1.6 million  a year),  of  which  D  10.9  million  (95.5%)  for  the  hospital-
izations,  D  246,000  (2.1%)  for pharmaceutical  treatment  and  D 270,000  (2.4%)  for specialist  outpatient
services.  The  average  annual  cost  per  patient  was D  3826,  of  which  D  3653  was  for  hospitalization,  while
pharmaceutical  expenditure  and specialist  services  accounted  for D  83  and  D  90,  respectively.  The  cohort
of  patients  undergoing  a ﬁrst  admission  for diverticulitis  between  2010  and  2013  was made  up of 1729
people  (54.4%  women,  mean  age 68.9 years),  of whom  1500  (86.8%)  did not  undergo  surgery  while  in hos-
pital.  Hospital  mortality,  recorded  only  for the  over-65  age  class,  averaged  1.2%;  for  patients  not  receiving
surgery during  the  initial  hospitalization  it was  0.5%,  reaching  5.2%  in  patients  undergoing  surgery.  The
percentage  of  patients  with  one  or more  readmissions  for diverticulitis  within  a year of  the  ﬁrst  was  on
average  7.8%  and  in  48%  of  cases  this  resulted  in  surgery.
Conclusions:  Our  study  is  the ﬁrst  analysis  in  Italy  to use real-world  data  to measure  the  ﬁnancial  impact
of  diverticular  disease.  Assuming  that  the  diagnostic  and  therapeutic  behaviour  identiﬁed  in the  Marche
region  could  be representative  of the  situation  nationwide,  the estimated  annual  number  of hospitaliza-
tions  in  Italy  for  acute  episodes  of  diverticulitis  is 19,000.  The  total  amount  of economic  resources  needed
to  treat  patients  suffering  from
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. Introduction
Diverticular disease (DD) covers a wide variety of conditions
ssociated with the presence of diverticula in the colon (herniation
f the colonic mucosa through the muscle layer). Of these, the most
erious condition is an acute episode of diverticulitis that, depend-
ng on its severity, can lead to hospitalization, surgery and may  even
esult in the patient’s death.
Traditionally, three factors are associated with the pathogen-
sis of DD: age, diet and bowel motility. In recent years, this list
as expanded to six with the addition of genetic factors, intestinal
nnervation and microbiota.
The incidence of diverticula is correlated with increasing age:
eery et al.’s study shows 16% of subjects are under the age of 40
ising to over 63% among the over 70 s [1].
Alterations of the connective tissue, such as greater cross-
inking of collagen ﬁbrils or altered expression of matrix
etalloproteinases, may  help to increase the onset of diverticula
ith age [2].
DD has also been correlated with Western lifestyle and lack of
hysical activity [3].
Focus on DD is increasing exponentially, as reﬂected also in the
umber of publications devoted to it.
Most diverticulosis cases remain asymptomatic for life: only
bout 4% of patients with an endoscopic diagnosis of diverticulosis
evelop diverticulitis [4]. Of these patients, around 15–30% undergo
 relapse and about 15% develop complications. Admissions for
iagnosis code diverticulitis without haemorrhage (562.11) are
ery much on the increase: in the USA alone, the increase in the
dmissions rate was +21% compared to 2003, with a hospital mor-
ality rate of 0.5% [5].
Over the years, different ways of reducing the risk of occurrence
nd recurrence of diverticulitis have been explored, with the most
romising ones including the use of non-absorbable antibiotics.
revention of acute episodes of diverticulitis as well as improve-
ents to DD patient management should reduce the number of
ospitalizations and, consequently, the direct costs arising from
D-related complications. An evidence-based review on the natu-
al history of DD and the role of treatment has just been published
6].
In the United States, according to data in the literature, annual
osts of diverticular disease are between 2.2 and 2.6 billion dollars,
aking it the ﬁfth most costly gastrointestinal disorder in terms of
irect and indirect costs [5].
Despite the signiﬁcant epidemiological burden, in Italy there
re currently no ﬁnancial evaluations available on a representative
ample of the population regarding the costs of diverticular disease
nd its complications.
The aim of this study is to evaluate the ﬁnancial impact gener-
ted by complications of diverticular disease using real-world data
rom the Marche region’s administrative database and to quantify
he patient outcome variables in the period following the index
dmission for diverticulitis.
. Data source and methods
.1. Data source
Admissions for diverticulitis were selected from the Marche
egion’s Hospital Information System, which records all admis-
ions to accredited public and private hospitals in the region. The
ischarge records include the patient’s demographic (gender, age,
ducation, residence) and clinical information, the diagnosis and
he main and secondary procedures (5 ﬁelds) as set out in the
nternational Classiﬁcation of Diseases (ICD-9-CM).r Disease 49 (2017) 1003–1008
Drug prescriptions were extracted from the Marche region’s
Pharmaceutical Prescription Information System, containing all
prescriptions sent to municipal and private pharmacies within the
region and reimbursed by the Italian National Health Service.
Specialist outpatient care was  selected from the Marche region’s
Specialist Service Information System, containing all outpatient
appointments for diagnostic and therapeutic services in the region.
A deterministic linkage was  performed at individual user level
between the different administrative sources through anonymous
ID number for a period of analysis between 1 January, 2008 and 31
December, 2014.
3. Methods
Prevalent cases of diverticulitis per year were identiﬁed by
selecting all persons residing in the Marche region with at least one
admission for “diverticulitis of the colon without mention of haem-
orrhage” (ICD-9-CM code 562.11) or “diverticulitis of the colon with
haemorrhage” (ICD-9-CM code 562.13) as primary diagnosis, or else
as secondary diagnosis where, however, the main diagnosis was
one of the diverticulitis-related diagnoses (see Annex).
For these subjects, we identiﬁed all prescriptions of intestinal
antibiotics (ATC A07AA), intestinal anti-inﬂammatory drugs (ATC
A07EC) and metronidazole (ATC J01XD01; P01AB01) as well as all
specialist outpatient services (see Annex) correlated with the dis-
ease which took place during the calendar year of admission.
The annual cost of diverticulitis was estimated by assigning a
value to each admission based on the Marche region’s tariff for hos-
pital services in force during the year of discharge, the cost of drugs
was estimated using the regional reimbursement price current at
the time of dispensing and outpatient specialist care was calcu-
lated using the current regional price in the year of provision of the
service.
Longitudinal analysis was performed by identifying the cohort
of patients admitted for diverticulitis in the three-year period from
2010–2013 with no prior admissions for diverticulitis in the pre-
vious two  years. If a patient had more than one admission during
these three years, their ﬁrst admission was  selected as the index
admission (Fig. 1).
Subjects were stratiﬁed by surgical procedure (large intestine,
small intestine or rectal resection) during the index admission; the
procedure was  identiﬁed using the DRG attributed on discharge
(see Supplementary Table S2).
Only subjects of legal age living in the Marche region at the time
of index admission were considered.
All enrolled subjects, once discharged from the index admission,
were followed for one year, and all subjects requiring re-admission
and/or surgery for diverticulitis during follow-up have been identi-
ﬁed. Annual costs were thus estimated taking into account the cost
of the index admission and any possible subsequent admissions
occurring during the year of observation(Table 1).
4. Results
The total number of subjects resident in the Marche region
who had at least one hospitalization for diverticulitis in the period
2008–2014 was  2987 (427 patients a year, corresponding to 35 per
100,000 adult residents) whereas the total number of admissions
was 3453 (just over 490 a year).
The number of hospitals of Marche region from which data have
been collected is 44. The number of admissions for each hospital
varied from 1 to 218.
On average, 75% of patients received at least one drug prescrip-
tion, from a list of drugs related to diverticular disease and granted
by the national health service (see Supplementary Table S3) in
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Fig. 1. Patient recruitment diagram—longitudinal analysis.
Table 1
Costs per year for patients admitted to hospital once or more for diverticulitis.
Year Subjects Hospitalizations Cost of hospitalizations Users Cost of drugs Patients Cost of specialist care Total
2008 435 460 D 1,527,352 317 D 34,639 271 D 25,485 D 1.587.477
2009  419 449 D 1,422,886 306 D 35,002 246 D 35,213 D 1.493.101
2010  412 438 D 1,328,730 301 D 31,671 236 D 30,561 D 1.390.962
2011  484 515 D 1,685,063 354 D 27,120 355 D 46,558 D 1.758.742
2012  494 530 D 1,516,335 369 D 30,926 320 D 37,128 D 1.584.389
2013  491 531 D 1,686,612 385 D 42,815 336 D 48,416 D 1.777.842

































iTotal  2987 3453 D 10,911,461 2
ource: Our processing of Marche regional data from 2008–2014.
he year of admission. In the same year, 66% beneﬁted from one
f the specialist outpatient services, selected as possibly related
o diverticular disease (the list of granted services is presented in
upplementary Table S4).
The healthcare costs covered by the Marche region for episodes
f diverticulitis between 2008 and 2014 was calculated as D 11.4
illion (approx. D 1.6 million a year), of which D 10.9 million
95.5%) for the hospitalizations, including drugs prescribed dur-
ng the admission, D 246,000 (2.1%) for outpatient pharmaceutical
reatment related to diverticular disease, and D 270,000 (2.4%) for
pecialist outpatient services (see Methods section).
The average annual cost per patient with at least one hos-
ital admission was D 3826, of which D 3653 for hospitalization,
hile regional pharmaceutical assistance and specialist services
ccounted for D 83 and D 90, respectively.
The cohort of patients undergoing a ﬁrst admission for diver-
iculitis between 2010 and 2013 was made up of a total of 1729
eople (54.4% women, mean age 68.9 years), of whom 1500 (86.8%)
id not undergo surgery during the index admission. During the
ndex admission, no statistically signiﬁcant differences were found
egarding gender (p value 0.4445) and age (p value 0.9748) between
hose undergoing surgery and those not.
Hospital mortality, recorded only in the over 65 age group, was
.2%; fairly obvious differences emerged between patients whose
ndex admission involved no surgery (0.5% mortality) and those
ho underwent surgery during the index admission (mortality
.2%). Among patients submitted to surgery in the index admission
229 or 13,2%), open or laparoscopic surgery have been performed
n 201 (87,8%) and in 28 (12,2%). Mortality in the ﬁrst admis-
ion affected 11 patients (5,5%) operated with the open technique,
gainst 1 (3,6%) operated in laparoscopy.
The percentage of patients with one or more readmissions for
iverticulitis in the year after the ﬁrst was on average 7.8% and in
8% of these cases the re-admission resulted in surgery.
Ten of patients (5%) who underwent open surgery had a sec-
nd admission and 4 (2%) had another intervention within 1 year,
n front of 0 (0)% of patients operated initially in laparoscopy. NoD 246,136 1968 D 270,091 D 11.427.688
attempt is allowed to identify statistical inference, due to the low
volume of laparoscopic surgery.
Ileostomy or colostomy were performed in 56 (27,9%) of oper-
ated patients with the open approach, and only in 2 (7,1%)
submitted to laparoscopy. Only 4 out of 58 (6,9%) underwent new
surgery for re-anastomosis in 1 year.
Among index-admission patients not undergoing surgery, the
raw percentage of re-admissions at one year is 8.2%, and would
seem to be inversely proportional to age (OR40–64VS <40 = 0.75
p = 0.424 and OR65+VS <40 = 0.41 p = 0.010). Approximately 50% of
re-admissions involved surgical procedures and the percentage
of repeat surgical procedures at one year is 1.8%; again there
is a inverse relationship with age (OR40–64VS <40 = 0.53 p = 0.105 e
OR65+VS <40 = 0.17 p = 0.001).
Within a year of index admission, patients undergoing surgery
had a lower percentage of readmissions (4.6%) and repeat surgical
procedures (1.8%) compared to those treated non-operatively (8.2%
readmissions and 4.0% surgical procedures, respectively).
The average annual cost per patient was  D 3403.43, depending
largely on the surgical procedure: patients treated non-operatively
during the index admission cost on average D 2472.99, rising to
D 9498.03 for subjects who underwent a surgical procedure during
the index admission.
The ﬁnancial weight of surgery can also be seen by focusing on
the cost of re-admissions: subjects treated non-operatively during
the index admission have a greater chance of being re-admitted for
surgery over the next 12 months (8.2% Table 2) than patients who
underwent a surgical procedure during the index admission (4.6%
Table 2). This has an impact on costs at one year for readmissions:
D 5585.58 for the ﬁrst cluster and D 3516.37 for the second.
5. DiscussionDiverticulosis is very common in Western countries, and its
prevalence increases with age. Most diverticulosis cases remain
asymptomatic for life: only about 4% of patients with an endoscopic
diagnosis of diverticulosis develop diverticulitis [5].
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Table 2

















No <40 73 (4.2%) 0 (0%) 10 (13.7%) 8 (11%)
40–64 462 (26.7%) 0 (0%) 54 (11.7%) 31 (6.7%)
65+  965 (55.8%) 8 (0.8%) 59 (6.2%) 21 (2.2%)
Sub-total 1.500 (86.8%) 8 (0.5%) 123 (8.2%) 60 (4%)
Yes <40  9 (0.5%) 0 (0%) 1 (11.1%) 1 (11.1%)
40–64 64 (3.7%) 0 (0%) 1 (1.6%) 1 (1.6%)
65+  156 (9%) 12 (7.7%) 8 (5.6%) 2 (1.4%)
Sub-total 229 (13.2%) 12 (5.2%) 10 (4.6%) 4 (1.8%)
Total  1729 20 (1.2%) 133 (7.8%) 64 (3.7%)
Source: Our processing of Marche regional data from 2008–2014.
Table 3









Average cost per patient
readmitted within 1 year
No <40 73 D 2798.47 10 D 8854.78
40–64 462 D 2291.34 54 D 5703.25
65+  965 D 2535.33 59 D 4923.78
Sub-total 1.500 D 2472.99 123 D 5585.58
Yes <40  9 D 8836.12 1 D 3841.00
40–64  64 D 8874.06 1 D 5976.00
65+  156 D 9792.20 8 D 3168.34






















bTotal  1729 D
ource: Our processing of Marche regional data from 2008–2014.
However, admissions for diagnosis code diverticulitis without
aemorrhage (562.11) are very much on the increase: in the USA
lone, the increase in the admissions rate was +21% compared to
003, with a total aggregate cost of between $2.2 and $2.6 billion
nd a hospital mortality rate of 0.5% [5].
Two very large multicentre studies [7,8] suggest that relapse
fter diverticulitis is not very severe. Broderick-Villa [8] reports
n the history of 2366 patients hospitalized for diverticulitis and
reated non-operatively in the Kaiser system. At a median follow-up
f 8.9 years, diverticulitis had recurred in 13.3% of patients and only
.9% had a second relapse. The risk of subsequent relapse increased
o 29% among patients who had a ﬁrst relapse (Table 3).
Binda et al.’s Italian study [7] reports on a follow-up of 320
atients treated with antibiotics in 17 hospitals after discharge for
iverticulitis. In a comparable follow-up period (10.7 years), 25% of
atients had symptoms requiring re-admission. The risk of surgery
ose to 17%. In the analysis corrected for risk factors, the risk of
ecurrence was highest among patients under age 50 and among
hose with 3 previous episodes of diverticulitis. Many studies on
ecurrence argue that the risk is concentrated in the ﬁrst 2 years of
ollow-up. Binda et al. [7], however, suggest that this ﬁgure remains
lmost constant throughout the follow-up period.
The data in this study can be summarized as follows:
a) the incidence of admissions for diverticulitis remained stable
from 2008 to 2010, and increased from 2011 to 2014 (+12% in
2014 v. 2008); caution should be used in evaluating this ﬁnding,
since a change in medical approach (e.g. defensive medicine)
could be the cause;
) within one year from the ﬁrst episode of diverticulitis, the inci-
dence of re-admission for diverticulitis was 8.2% in patients
treated non-operatively (Table 2). However, recurrence at one
year can occur even in patients undergoing surgery (4.6%,
Table 2) demonstrating that the role of surgery should always.43 133 D 5430.00
be carefully evaluated. It should be noted that these ﬁgures are
subject to bias with regard to the deﬁnition of recurrence (recur-
rences recorded are limited to those requiring re-admission);
c) during the observation period, no cases of patients suffering
from a second relapse were recorded;
d) acute episodes of diverticulitis involve a risk of mortality in
patients over the age of 65 (1.2%).
The clinical evolution of the index admission is summarized in
Fig. 2.
From a ﬁnancial standpoint, we  estimate that the average annual
cost per patient is over D 3400. The average cost is signiﬁcantly
affected by the performance or otherwise of a surgical procedure
during the index admission; patients treated non-operatively dur-
ing the index admission cost an annual average of about D 2470,
whereas patients with surgery cost around 4 times that, at D 9490.
These data are consistent with the literature.
For example, a study conducted in the USA on 132 patients esti-
mated an average cost of between $3458 and $4321, depending on
the procedure performed [9]. A similar study, conducted on 144
patients in the UK estimated an average cost of £3143 [10], while
an analysis carried out in Italy on 738 patients discharged from the
Federico II University Hospital in Naples between 2004 and 2010
estimated a cost per patient amounting to D 2250, a ﬁgure which
the authors regard as an underestimate as there was no emergency
room in the facility [11].
It is interesting to note that in our study we found that the dif-
ferences between patients undergoing surgery during the index
admission and those who did not are reversed when we consider
only those patients who were re-admitted once or more within one
year of initial admission. In such cases, indeed, the estimated cost
for patients not undergoing surgery during the index admission
were over 50% higher than for those undergoing surgery, amount-
ing to D 5500 and D 3500, respectively.































aFig. 2. The clinical evol
Assuming that the diagnostic and therapeutic behaviour in the
arche region could be representative of the situation nationwide,
otal annual expenditure in terms of direct costs for the Italian
ational Health Service can be estimated at over D 63 million. This
gure does not include the costs for drug treatments and diagnostic
rocedures, not to mention the indirect costs, that in most cost-of-
llness estimates make up over 50% of the costs incurred by society
12–17].
Like all analyses based on claims databases, this paper too has
ts limitations.
First, the analysis is based on administrative data sources which,
y their very nature, were not designed to be used for epidemio-
ogical purposes, but only for accounting and billing. However, to
ate, there are no speciﬁc epidemiological registries for measuring
iverticulitis patients’ clinical outcomes, which means that admin-
strative sources remain the best alternative possible for tracking
atients’ therapeutic diagnostic process.
A second limitation of the study is the difﬁculty inherent in
dentifying which patient-related clinical variables to analyse. This
eans that some bias may  persist linked to the severity of the dis-
ase and, more generally, to the clinical history of the patients in the
nalysis. In this case, the high sample size (more than 3500 admis-
ions covering 2900 patients) and the stratiﬁcation of subjects by
ge suggest that the estimates obtained are sufﬁciently robust.
Finally, another limitation regards estimates of patient mortal-
ty. In this case, the analysis referred only to hospital mortality,
gnoring anything occurring post-discharge outside the conﬁnes of
he hospital. This makes it impossible to identify deaths occurring
utside the hospital environment, leading to an underestimation
f patient mortality and readmission rates.
This study outlines various prospects for the future control of
iverticular disease and for the incidence of diverticulitis.
While the patient’s age obviously cannot be changed, more
eeds to be done to identify and learn about the risk factors (i.e.
omorbidities, compliance and hospital stay) that can increase the
ikelihood of a relapse and thus of a readmission.
A better understanding of the weight of the risk factors has
lready highlighted some key points, in particular the use of NSAIDsof the index admission.
and aspirin. NSAIDs, including aspirin, are now considered risk fac-
tors for diverticulitis because they cause local damage directly in
the colon, compromise the integrity of the mucosa and inhibit the
synthesis of prostaglandins.
Several studies have found a positive association between
NSAIDs and diverticulitis. However, most of them have evaluated
the concomitant use of NSAIDs and aspirin. Aspirin plays a very
signiﬁcant role in preventing chronic diseases, especially in the sec-
ondary prevention of cardiovascular events. It would be useful to
understand the weight of aspirin alone in inducing diverticulitis, so
as to help decide whether it can continue to be taken by patients
with a history of diverticulitis.
Strate et al.’s study [18] suggests that using aspirin alone raises
the risk of the ﬁrst episode by 45% (HR 1.46, CI 95% 1.13–1.88).
However, there are no known data on the recurrence of divertic-
ulitis. Some epidemiological assumptions, however, would suggest
there is an increased diverticulitis recurrence risk in 5 out of every
100 patients over a 5-year follow-up period (95% conﬁdence inter-
vals from 1 to 9) [19].
While aspirin and NSAIDs are identiﬁed as risk factors for the
ﬁrst episode of diverticulitis, the weight of using them in those
who have already had diverticulitis has yet to be directly quanti-
ﬁed. Further research will be needed to weigh the role of aspirin
and NSAIDs in these patients, taking into account that both classes
of molecules are widely used and in some locations also play an
increasing role in cancer prevention [20].
In this sense, further investigations into the data from this real-
world study may  correct the risk of using NSAIDs and aspirin in
Italy.
Is there any evidence that medical treatment can reduce the risk
of a ﬁrst episode of diverticulitis and relapse?
From what we have found in the literature, it would very much
seem that there is still rather little evidence in the therapeutic
management of patients with a history of diverticulitis. This is sur-
prising, since the direct and indirect ﬁnancial costs of diverticular
disease are concentrated especially in episodes of diverticulitis and
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es with the aim of evaluating various therapies in such patients
ill be needed.
Finally there is the matter of elective surgery to prevent relapse.
he issue is still being debated [19] and the discussion is outside the
cope of this paper. However, it is evident that even from this real-
orld study that surgery does not exclude the risk of recurrence:
.6% of patients operated on in the Marche region during the index
dmission were re-admitted within the next 12 months following
 relapse (Table 2).
In conclusion, the estimated annual number of hospitalizations
n Italy for acute episodes of diverticulitis is 19,000, assuming
hat the diagnostic and therapeutic behaviour identiﬁed in the
arche region is representative of the situation nationwide. The
otal amount of direct ﬁnancial resources needed to treat patients
uffering from acute episodes of diverticulitis can be estimated at
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